Detail

Haloperidol

Description

Name: Haloperidol
Type: small molecule
Groups: approved
Indication: For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
Accession Number: DB00502 ( APRD00538)
Description: A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Haldolinjection5 mg/mLintramuscular18-05-1971US
Haldol Decanoateinjection50 mg/mLintramuscular14-01-1986US
Haldol Decanoateinjection100 mg/mLintramuscular14-01-1986US
Haldol Injection 5mg/mlliquid5 mgintramuscular31-12-196604-08-2006Canada
Haldol LA Inj 100mg/mlliquid100 mgintramuscular31-12-198304-08-2006Canada
Haldol LA Inj 50mg/mlliquid50 mgintramuscular31-12-198323-01-2006Canada
Haloperidolinjection5 mg/mLintramuscular29-06-2011US
Haloperidolinjection5 mg/1intramuscular10-04-2013US
Haloperidolinjection5 mg/mLintramuscular17-06-2011US
Haloperidol Decanoateinjection50 mg/mLintramuscular17-06-2011US
Haloperidol Decanoateinjection100 mg/mLintramuscular17-06-2011US
Haloperidol Decanoate Inj. Liq Im 100mg/mlliquid100 mgintramuscular31-12-199513-08-1998Canada
Haloperidol Decanoate Inj. Liq Im 50mg/mlliquid50 mgintramuscular31-12-199513-08-1998Canada
Haloperidol Decanoate Injectionsolution50 mgintramuscular01-01-1970Canada
Haloperidol Decanoate Injectionsolution100 mgintramuscular01-01-1970Canada
Haloperidol Decanoate Injectionliquid50 mgintramuscular01-01-1970Canada
Haloperidol Decanoate Injectionliquid100 mgintramuscular01-01-1970Canada
Haloperidol Inj 5mg/ml USPliquid5 mgintramuscular31-12-1989Canada
Haloperidol Injectionsolution5 mgintramuscular19-09-2011Canada
Haloperidol Injection, USPsolution5 mgintramuscular20-10-2014Canada
Haloperidol LAliquid50 mgintramuscular31-12-1994Canada
Haloperidol LAliquid100 mgintramuscular31-12-1994Canada
Haloperidol Long Actingliquid100 mgintramuscular02-08-200110-08-2005Canada
Haloperidol Long Actingliquid50 mgintramuscular02-08-200110-08-2005Canada
Haloperidol Tab 0.5mgtablet.5 mgoral31-12-198313-07-2010Canada
Haloperidol Tab 1mgtablet1 mgoral31-12-198313-07-2010Canada
Haloperidol Tab 2mgtablet2 mgoral31-12-198813-07-2010Canada
Haloperidol Tab 5mgtablet5 mgoral31-12-198813-07-2010Canada
Haloperidol-10 Tab 10mgtablet10 mgoral31-12-198813-07-2010Canada
Haloperidol-LA Omegaliquid50 mgintramuscular30-06-1999Canada
Haloperidol-LA Omegaliquid100 mgintramuscular28-05-1999Canada
Novo-peridoltablet20 mgoral31-12-1988Canada
Novo-peridoltablet0.5 mgoral31-12-1986Canada
Novo-peridoltablet1 mgoral31-12-1986Canada
Novo-peridoltablet2 mgoral31-12-1986Canada
Novo-peridoltablet10 mgoral31-12-1986Canada
Novo-peridoltablet5 mgoral31-12-1984Canada
Novo-peridol Oral Soln 2mg/mlsolution2 mgoral31-12-198710-08-2005Canada
Nu-haloperidoltablet0.5 mgoral01-01-1970Canada
Nu-haloperidoltablet1 mgoral01-01-1970Canada
Nu-haloperidoltablet2 mgoral01-01-1970Canada
Nu-haloperidoltablet5 mgoral01-01-1970Canada
Nu-haloperidoltablet10 mgoral01-01-1970Canada
PMS-haloperidol Soln 2mg/mlsolution2 mgoral31-12-1988Canada
PMS-haloperidol-LAliquid50 mgintramuscular24-09-1997Canada
PMS-haloperidol-LAliquid100 mgintramuscular17-08-1997Canada
Ratio-haloperidol 2mg/mlsolution2 mgoral31-12-198204-08-2006Canada
Ratio-haloperidol Tab 0.5mgtablet.5 mgoral31-12-198204-08-2006Canada
Ratio-haloperidol Tab 10mgtablet10 mgoral31-12-198704-08-2006Canada
Ratio-haloperidol Tab 1mgtablet1 mgoral31-12-198204-08-2006Canada
Ratio-haloperidol Tab 2mgtablet2 mgoral31-12-198704-08-2006Canada
Ratio-haloperidol Tab 5mgtablet5 mgoral31-12-198504-08-2006Canada
Rho-haloperidol Decanoate Inj.-im 100mg/mlsolution100 mgintramuscular07-05-199701-08-2005Canada
Rho-haloperidol Decanoate Inj.-im 50mg/mlsolution50 mgintramuscular07-05-199701-08-2005Canada

Generic Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Apo Haloperidol Liq 2mg/mlliquid2 mgoral31-12-1983Canada
Apo Haloperidol Tab 0.5mgtablet.5 mgoral31-12-1980Canada
Apo Haloperidol Tab 1mgtablet1 mgoral31-12-1980Canada
Apo-haloperidol LA Injectableliquid50 mgintramuscular30-06-200002-08-2013Canada
Apo-haloperidol LA Injectableliquid100 mgintramuscular30-06-200002-08-2013Canada
Apo-haloperidol Tab 10mgtablet10 mgoral31-12-1987Canada
Apo-haloperidol Tab 2mgtablet2 mgoral31-12-1987Canada
Apo-haloperidol Tab 5mgtablet5 mgoral31-12-1987Canada
Haloperidolsolution2 mg/mLoral28-09-1993US
Haloperidoltablet5 mg/1oral10-06-1986US
Haloperidoltablet10 mg/1oral17-07-2009US
Haloperidoltablet20 mg/1oral17-07-2009US
Haloperidoltablet.5 mg/1oral10-06-1986US
Haloperidoltablet10 mg/1oral01-01-2013US
Haloperidoltablet2 mg/1oral01-07-2009US
Haloperidoltablet.5 mg/1oral29-04-1999US
Haloperidolinjection, solution5 mg/mLintramuscular10-05-2011US
Haloperidoltablet2 mg/1oral01-07-2009US
Haloperidoltablet5 mg/1oral03-01-2008US
Haloperidoltablet1 mg/1oral17-11-1986US
Haloperidoltablet10 mg/1oral03-01-2008US
Haloperidolsolution, concentrate2 mg/mLoral01-12-1988US
Haloperidoltablet20 mg/1oral03-01-2008US
Haloperidolinjection5 mg/mLintramuscular01-03-2002US
Haloperidolinjection5 mg/mLintramuscular01-03-2002US
Haloperidoltablet20 mg/1oral19-02-2013US
Haloperidolinjection, solution5 mg/mLintramuscular10-05-2011US
Haloperidoltablet.5 mg/1oral01-02-2004US
Haloperidoltablet1 mg/1oral01-02-2004US
Haloperidoltablet2 mg/1oral15-02-2004US
Haloperidoltablet5 mg/1oral15-02-2004US
Haloperidoltablet.5 mg/1oral17-11-1986US
Haloperidoltablet1 mg/1oral17-11-1986US
Haloperidoltablet.5 mg/1oral17-11-1986US
Haloperidoltablet5 mg/1oral17-11-1986US
Haloperidoltablet1 mg/1oral17-11-1986US
Haloperidoltablet2 mg/1oral17-11-1986US
Haloperidoltablet5 mg/1oral17-11-1986US
Haloperidoltablet5 mg/1oral28-07-2010US
Haloperidoltablet2 mg/1oral17-11-1986US
Haloperidoltablet10 mg/1oral11-03-1988US
Haloperidoltablet10 mg/1oral15-09-2011US
Haloperidoltablet1 mg/1oral05-09-2012US
Haloperidoltablet5 mg/1oral03-01-2008US
Haloperidoltablet2 mg/1oral05-09-2012US
Haloperidoltablet10 mg/1oral03-01-2008US
Haloperidoltablet20 mg/1oral03-01-2008US
Haloperidoltablet10 mg/1oral04-03-2008US
Haloperidoltablet20 mg/1oral02-04-2008US
Haloperidoltablet1 mg/1oral17-11-1986US
Haloperidoltablet2 mg/1oral01-01-2013US
Haloperidoltablet1 mg/1oral10-06-1986US
Haloperidoltablet.5 mg/1oral05-09-2012US
Haloperidoltablet5 mg/1oral10-06-1986US
Haloperidoltablet10 mg/1oral03-01-2008US
Haloperidolinjection, solution5 mg/mLintramuscular13-06-2013US
Haloperidoltablet1 mg/1oral19-02-2009US
Haloperidoltablet2 mg/1oral19-02-2009US
Haloperidoltablet5 mg/1oral01-01-2014US
Haloperidoltablet5 mg/1oral19-02-2009US
Haloperidoltablet10 mg/1oral25-03-2015US
Haloperidoltablet1 mg/1oral01-07-2009US
Haloperidoltablet.5 mg/1oral13-01-2011US
Haloperidoltablet5 mg/1oral08-02-2016US
Haloperidoltablet1 mg/1oral13-01-2011US
Haloperidoltablet2 mg/1oral13-01-2011US
Haloperidoltablet5 mg/1oral13-01-2011US
Haloperidolsolution2 mg/mLoral08-09-2009US
Haloperidoltablet10 mg/1oral11-03-1988US
Haloperidoltablet.5 mg/1oral13-05-2014US
Haloperidoltablet5 mg/1oral17-11-1986US
Haloperidoltablet2 mg/1oral10-06-1986US
Haloperidoltablet2 mg/1oral01-07-2013US
Haloperidolinjection5 mg/mLintramuscular19-06-2001US
Haloperidoltablet2 mg/1oral21-10-2011US
Haloperidolinjection5 mg/mLintramuscular29-08-2001US
Haloperidoltablet5 mg/1oral10-06-1986US
Haloperidoltablet5 mg/1oral21-12-2010US
Haloperidoltablet.5 mg/1oral17-11-1986US
Haloperidoltablet1 mg/1oral17-11-1986US
Haloperidoltablet2 mg/1oral17-11-1986US
Haloperidoltablet5 mg/1oral17-11-1986US
Haloperidoltablet10 mg/1oral11-03-1988US
Haloperidoltablet20 mg/1oral11-03-1988US
Haloperidolinjection5 mg/mLintramuscular29-09-2014US
Haloperidolinjection, solution5 mg/mLintramuscular20-10-2000US
Haloperidolsolution, concentrate2 mg/mLoral10-11-2009US
Haloperidoltablet5 mg/1oral10-04-2013US
Haloperidoltablet5 mg/1oral01-07-2009US
Haloperidoltablet5 mg/1oral01-07-2009US
Haloperidoltablet5 mg/1oral24-10-1996US
Haloperidoltablet1 mg/1oral26-07-1995US
Haloperidolinjection, solution5 mg/mLintramuscular15-12-2010US
Haloperidoltablet10 mg/1oral03-08-2009US
Haloperidoltablet2 mg/1oral10-06-1986US
Haloperidolinjection, solution5 mg/mLintramuscular24-10-2011US
Haloperidolinjection, solution5 mg/mLintramuscular24-10-2011US
Haloperidoltablet2 mg/1oral20-12-2010US
Haloperidoltablet1 mg/1oral10-06-1986US
Haloperidoltablet5 mg/1oral15-02-2004US
Haloperidol Decanoateinjection50 mg/mLintramuscular04-06-1999US
Haloperidol Decanoateinjection50 mg/mLintramuscular01-07-1999US
Haloperidol Decanoateinjection100 mg/mLintramuscular04-06-1999US
Haloperidol Decanoateinjection100 mg/mLintramuscular01-07-1999US
Haloperidol Decanoateinjection100 mg/mLintramuscular12-07-2000US
Haloperidol Decanoateinjection50 mg/mLintramuscular16-02-2000US
Haloperidol Decanoateinjection100 mg/mLintramuscular12-07-2000US
Haloperidol Decanoateinjection50 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection50 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection100 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection100 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection100 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection50 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection100 mg/mLintramuscular23-04-2013US
Haloperidol Decanoateinjection50 mg/mLintramuscular23-04-2013US
Haloperidol Lactateinjection, solution5 mg/mLintramuscular10-05-2011US
Haloperidol Lactateinjection, solution5 mg/mLintramuscular10-05-2011US
Haloperidol Lactateinjection5 mg/mLintramuscular13-10-2015US

Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haldol DecanoateHaloperidol
Haldol DecanoateHaloperidol
HaldolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol LactateHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol LactateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol DecanoateHaloperidol
Haloperidol LactateHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
HaloperidolHaloperidol
Haloperidol Inj 5mg/ml USPHaloperidol
Haloperidol LAHaloperidol
Haloperidol LAHaloperidol
Apo Haloperidol Tab 0.5mgHaloperidol
Apo Haloperidol Tab 1mgHaloperidol
PMS-haloperidol-LAHaloperidol
PMS-haloperidol-LAHaloperidol
Apo Haloperidol Liq 2mg/mlHaloperidol
Novo-peridolHaloperidol
Haloperidol-LA OmegaHaloperidol
Haloperidol-LA OmegaHaloperidol
Novo-peridolHaloperidol
Novo-peridolHaloperidol
Novo-peridolHaloperidol
Novo-peridolHaloperidol
Apo-haloperidol Tab 2mgHaloperidol
Apo-haloperidol Tab 5mgHaloperidol
Apo-haloperidol Tab 10mgHaloperidol
Novo-peridolHaloperidol
Haloperidol InjectionHaloperidol
PMS-haloperidol Soln 2mg/mlHaloperidol
Haloperidol Injection, USPHaloperidol
Haloperidol Decanoate Inj. Liq Im 50mg/mlHaloperidol
Haloperidol Decanoate Inj. Liq Im 100mg/mlHaloperidol
Rho-haloperidol Decanoate Inj.-im 50mg/mlHaloperidol
Rho-haloperidol Decanoate Inj.-im 100mg/mlHaloperidol
Ratio-haloperidol 2mg/mlHaloperidol
Ratio-haloperidol Tab 0.5mgHaloperidol
Ratio-haloperidol Tab 1mgHaloperidol
Haloperidol Tab 1mgHaloperidol
Haloperidol Tab 0.5mgHaloperidol
Haldol LA Inj 50mg/mlHaloperidol
Haldol LA Inj 100mg/mlHaloperidol
Haloperidol Long ActingHaloperidol
Ratio-haloperidol Tab 5mgHaloperidol
Apo-haloperidol LA InjectableHaloperidol
Apo-haloperidol LA InjectableHaloperidol
Haloperidol Long ActingHaloperidol
Ratio-haloperidol Tab 2mgHaloperidol
Ratio-haloperidol Tab 10mgHaloperidol
Haldol Injection 5mg/mlHaloperidol
Novo-peridol Oral Soln 2mg/mlHaloperidol
Haloperidol Tab 2mgHaloperidol
Haloperidol Tab 5mgHaloperidol
Haloperidol-10 Tab 10mgHaloperidol
Haloperidol Decanoate InjectionHaloperidol
Haloperidol Decanoate InjectionHaloperidol
Nu-haloperidolHaloperidol
Nu-haloperidolHaloperidol
Nu-haloperidolHaloperidol
Nu-haloperidolHaloperidol
Nu-haloperidolHaloperidol
Haloperidol Decanoate InjectionHaloperidol
Haloperidol Decanoate InjectionHaloperidol
HaloperidolHaloperidol

Categories
  • Antipsychotic Agents
  • Butyrophenones
  • Antidyskinetics

Pharmacology

Indication: For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
Pharmacodynamics: Not Available
Mechanism of action: The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.
Absorption: Oral-60%
Volume of distribution: Not Available
Protein binding: 92%
Metabolism: Not Available
Route of elimination: Not Available
Half life: 3 weeks
Clearance: Not Available
Toxicity: LD50=165 mg/kg (rats, oral)
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Ortho mcneil pharmaceutical
  • Ortho mcneil pharmaceutical inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Roxane laboratories inc
  • Royce laboratories inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Alpharma uspd inc
  • Morton grove pharmaceuticals inc
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Ortho mcneil janssen pharmaceuticals inc
  • Abraxis pharmaceutical products
  • Akorn strides llc
  • Gland pharma ltd
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Actavis mid atlantic llc

Packagers:
Dosage forms
FormRouteStrength
Liquidoral2 mg
Tabletoral.5 mg
Tabletoral1 mg
Injectionintramuscular5 mg/1
Injectionintramuscular5 mg/mL
Injection, solutionintramuscular5 mg/mL
Solutionoral2 mg/mL
Solution, concentrateoral2 mg/mL
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral10 mg/1
Tabletoral2 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Injectionintramuscular100 mg/mL
Injectionintramuscular50 mg/mL
Liquidintramuscular5 mg
Solutionintramuscular5 mg
Liquidintramuscular100 mg
Liquidintramuscular50 mg
Tabletoral0.5 mg
Tabletoral10 mg
Tabletoral2 mg
Tabletoral20 mg
Tabletoral5 mg
Solutionoral2 mg
Solutionintramuscular100 mg
Solutionintramuscular50 mg

Prices
Unit descriptionCostUnit
Haloperidol 10 mg tablet$1.46tablet
Haloperidol 20 mg tablet$2.81tablet
Haloperidol lac 5 mg/ml vial$3.54ml
Haloperidol 5 mg/ml$4.73ml
Haloperidol La 50 mg/ml$7.71ml
Haldol 5 mg/ml ampul$13.4ml
Haloperidol La 100 mg/ml$15.42ml
Haloperidol dec 50 mg/ml vial$17.71ml
Haloperidol powder$21.42g
Haloperidol dec 100 mg/ml vial$29.85ml
Haldol decanoate 50 ampul$56.53ml
Haldol decanoate 100 ampul$107.77ml
Haloperidol Decanoate 100 mg/ml Solution 5ml Vial$257.14vial
Apo-Haloperidol 0.5 mg Tablet$0.04tablet
Novo-Peridol 0.5 mg Tablet$0.04tablet
Apo-Haloperidol 1 mg Tablet$0.06tablet
Novo-Peridol 1 mg Tablet$0.06tablet
Apo-Haloperidol 2 mg Tablet$0.11tablet
Novo-Peridol 2 mg Tablet$0.11tablet
Apo-Haloperidol 10 mg Tablet$0.14tablet
Novo-Peridol 10 mg Tablet$0.14tablet
Apo-Haloperidol 5 mg Tablet$0.16tablet
Novo-Peridol 5 mg Tablet$0.16tablet
Pernox scrub cleanser$0.18g
Haloperidol 0.5 mg tablet$0.25tablet
Haloperidol 1 mg tablet$0.36tablet
Haloperidol lac 2 mg/ml conc$0.45ml
Haloperidol 2 mg tablet$0.49tablet
Novo-Peridol 20 mg Tablet$0.66tablet
Haloperidol 5 mg tablet$0.8tablet

Patents
CountryPatent NumberApprovedExpires (estimated)

Interactions

Drug Interactions
DrugInteraction
AbirateroneThe serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Haloperidol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Haloperidol.
AmisulprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Haloperidol.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Haloperidol.
AmphetamineHaloperidol may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Haloperidol.
AzelastineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Haloperidol.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.
BenzphetamineHaloperidol may decrease the stimulatory activities of Benzphetamine.
BexaroteneThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
Botulinum Toxin Type AHaloperidol may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BHaloperidol may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
BromocriptineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Bromocriptine.
BuprenorphineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Haloperidol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.
CarbamazepineThe metabolism of Haloperidol can be increased when combined with Carbamazepine.
CathinoneHaloperidol may decrease the stimulatory activities of Cathinone.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Haloperidol.
Cimetropium BromideHaloperidol may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Haloperidol.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Haloperidol.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
ConivaptanThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Haloperidol.
DabrafenibThe serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Haloperidol.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.
DextroamphetamineHaloperidol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Haloperidol.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.
DofetilideHaloperidol may increase the QTc-prolonging activities of Dofetilide.
DonepezilDonepezil may increase the central neurotoxic activities of Haloperidol.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Haloperidol.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Haloperidol.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Haloperidol.
EluxadolineHaloperidol may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Haloperidol.
EthanolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Haloperidol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.
FluconazoleThe metabolism of Haloperidol can be decreased when combined with Fluconazole.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Haloperidol.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.
FluvoxamineThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
FosaprepitantThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.
Fusidic AcidThe serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.
GalantamineGalantamine may increase the central neurotoxic activities of Haloperidol.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Glucagon recombinant.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.
GlycopyrrolateThe serum concentration of Haloperidol can be decreased when it is combined with Glycopyrrolate.
GoserelinGoserelin may increase the QTc-prolonging activities of Haloperidol.
HydrocodoneHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.
IdelalisibThe serum concentration of Haloperidol can be increased when it is combined with Idelalisib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Haloperidol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Haloperidol.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Haloperidol.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Haloperidol.
IvabradineIvabradine may increase the QTc-prolonging activities of Haloperidol.
IvacaftorThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Haloperidol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Haloperidol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.
LisdexamfetamineHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Haloperidol.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Haloperidol.
LuliconazoleThe serum concentration of Haloperidol can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Haloperidol.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
MequitazineHaloperidol may increase the arrhythmogenic activities of Mequitazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
MethamphetamineHaloperidol may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.
MetyrosineHaloperidol may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Haloperidol.
MifepristoneMifepristone may increase the QTc-prolonging activities of Haloperidol.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Haloperidol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
MirabegronThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mirabegron.
MirtazapineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Haloperidol can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Haloperidol.
MorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Haloperidol.
NelfinavirThe metabolism of Haloperidol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Haloperidol can be increased when it is combined with Netupitant.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Haloperidol.
OctreotideOctreotide may increase the QTc-prolonging activities of Haloperidol.
OrphenadrineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
PalbociclibThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.
ParaldehydeHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Haloperidol.
PhendimetrazineHaloperidol may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.
PhentermineHaloperidol may decrease the stimulatory activities of Phentermine.
PhenytoinThe metabolism of Haloperidol can be increased when combined with Phenytoin.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
Potassium ChlorideHaloperidol may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Haloperidol.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Haloperidol.
PromazinePromazine may increase the QTc-prolonging activities of Haloperidol.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Haloperidol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Haloperidol.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.
QuinidineHaloperidol may increase the QTc-prolonging activities of Quinidine.
RamosetronHaloperidol may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.
RitonavirThe metabolism of Haloperidol can be decreased when combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Haloperidol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Haloperidol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Haloperidol.
SiltuximabThe serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Haloperidol.
St. John's WortThe serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Haloperidol can be increased when it is combined with Stiripentol.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.
SulpirideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.
SuvorexantHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Tacrine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.
ThalidomideHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.
TiclopidineThe metabolism of Haloperidol can be decreased when combined with Ticlopidine.
TiotropiumHaloperidol may increase the anticholinergic activities of Tiotropium.
TocilizumabThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.
TopiramateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Haloperidol.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Haloperidol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Haloperidol.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Haloperidol.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Haloperidol.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Haloperidol.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.
ZolpidemHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Food Interactions:
  • Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Acetophenones
  • Aralkylamines
  • Aryl alkyl ketones
  • Aryl chlorides
  • Aryl fluorides
  • Azacyclic compounds
  • Benzoyl derivatives
  • Butyrophenones
  • Chlorobenzenes
  • Fluorobenzenes
  • Gamma-amino ketones
  • Hydrocarbon derivatives
  • Organochlorides
  • Organofluorides
  • Phenylbutylamines
  • Tertiary alcohols
  • Trialkylamines

substituent:
  • Acetophenone
  • Alcohol
  • Amine
  • Aralkylamine
  • Aromatic heteromonocyclic compound
  • Aryl alkyl ketone
  • Aryl chloride
  • Aryl fluoride
  • Aryl halide
  • Aryl ketone
  • Azacycle
  • Benzenoid
  • Benzoyl
  • Butyrophenone
  • Carbonyl group
  • Chlorobenzene
  • Fluorobenzene
  • Gamma-aminoketone
  • Halobenzene
  • Hydrocarbon derivative
  • Ketone
  • Monocyclic benzene moiety
  • Organochloride
  • Organofluoride
  • Organohalogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Phenylbutylamine
  • Phenylpiperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine

References

Synthesis Reference: "DrugSyn.org":http://www.drugsyn.org/Haloperidol.htm
General Reference: # Niemegeers CJ, Laduron PM: Pharmacology and biochemistry of haloperidol. Proc R Soc Med. 1976;69 suppl 1:3-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14331
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic/haloper.htm
Drugs.comhttp://www.drugs.com/cdi/haloperidol.html

ATC Codes:
  • Array

AHFS Codes:
  • 28:16.08.08

MSDS: Download

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
SiteLock

© Copyright 2017
The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society.
The Purple Society, a not-for-profit, section 501(c)(3) 
#273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

or

Log in with your credentials

Forgot your details?